checkAd

    EQS-Adhoc  175  0 Kommentare Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil - Seite 3


     
    End of Announcement EQS Group News Service

    1251542  24-Nov-2021 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1251542&application_name=news&site_id=wallstreet

    Lesen Sie auch


    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    EQS-Adhoc Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil - Seite 3 EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Regulatory Admission Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil …